GREY:AKLPF - Post by User
Post by
Biostocks01on Aug 18, 2010 9:14pm
613 Views
Post# 17363515
OUTLOOK -AKL
OUTLOOK -AKLIndisputable progress...
We look forward to further growth in our PharmaForm subsidiary as well as continued development of Akela's lead compound Fentanyl Taifun(R) during the remainder of the year," said
Greg McKee, President and Chief Executive Officer.
The facts:
Pharmaform in the second quarter of 2010 direct costs were reduced by 30% with SG&A costs
seeing a reduction of 14% over the same period in 2009. PharmaForm ended the quarter with
positive EBITDA.
Teikoku Seiyaku Co. Ltd. ...We received
.2 million upon signing of the
amendment, and would receive $1.8 million subject to meeting a near term development milestone related to the
pharmaceutical development of the Product. On February 11, 2010, this milestone was achieved. The remaining
$1.8 million was received by Akela on August 6, 2010.
We believe our Fentanyl TAIFUN® product
candidate is currently in a lead position and anticipate it will become the first approved inhaled fentanyl product. In
addition to inhaled fentanyl, several new oral and intranasal products are in development. These products are
expected to increase substantially the market for fentanyl in the treatment of break-through cancer pain. We believe
that Fentanyl TAIFUN® will provide the fastest onset of pain relief.
Only 31,000,000 of shares assigning a strong potential of increase
Bio...